FDA approves generic version of doxil to address shortage.

The US Food and Drug Administration (FDA) has approved the first generic version of the cancer drug Doxil (doxorubicin liposome). The drug is approved to treat Kaposi sarcoma, ovarian cancer, and multiple myeloma. It is also sometimes used for other types of cancer, such as breast cancer. Doxorubicin liposome is currently on the FDA’s drug shortage list. The FDA’s Office of Generic Drugs is speeding up its review of generic applications to help resolve the shortages. Read more here.